Pancreatic Cancer Research

ResearcherOU Health Stephenson Cancer CenterActive in the last 2 years

Hassan A. Hatoum

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7553-1963; OpenAlex author ID A5057537682. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers

Papers 8

  1. NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI … Co-author DOI 10.1016/j.esmoop.2025.106043↗
  2. Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgr… Co-author DOI 10.1016/j.esmoop.2026.108307↗
  3. Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial. Co-author DOI 10.1080/14796694.2026.2664776↗
  4. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  5. Treatment of locally advanced pancreatic cancer using localized trans-arterial micro perfusion of gemcitabine: combined analysis of RR1 and RR2. Co-author DOI 10.1093/oncolo/oyae178↗
  6. A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable … Co-author DOI 10.1097/sla.0000000000004669↗
  7. The evolving role of radiation in pancreatic cancer. Co-author DOI 10.3389/fonc.2022.1060885↗
  8. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Co-author DOI 10.1002/cam4.2425↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eileen Mary O'Reilly · 4 shared papers, 2019–2026 · strength 0.81
  2. Zev A. Wainberg · 3 shared papers, 2026 · strength 0.73
  3. Andrew Scott Paulson · 2 shared papers, 2026 · strength 0.46
  4. Roberto Pazo-Cid · 2 shared papers, 2026 · strength 0.46
  5. Davide Melisi · 2 shared papers, 2026 · strength 0.46
  6. Vincent M. Chung · 2 shared papers, 2026 · strength 0.46
  7. Tanios Bekaii‐Saab · 2 shared papers, 2026 · strength 0.46
  8. Richard A Hubner · 2 shared papers, 2026 · strength 0.46
  9. Shubham Pant · 2 shared papers, 2026 · strength 0.46
  10. Eric Van Cutsem · 2 shared papers, 2026 · strength 0.46
  11. Teresa Mercade Macarulla · 2 shared papers, 2026 · strength 0.46
  12. Andrea J. Bullock · 2 shared papers, 2019–2026 · strength 0.35
  13. Farshid Dayyani · 1 shared paper, 2026 · strength 0.28
  14. Maen Abdelrahim · 1 shared paper, 2026 · strength 0.28
  15. Gazala Naaz Khan · 1 shared paper, 2026 · strength 0.28
  16. Noelle K. LoConte · 2 shared papers, 2019–2022 · strength 0.19
  17. Peter Muscarella · 1 shared paper, 2024 · strength 0.18
  18. Barish H. Edil · 1 shared paper, 2024 · strength 0.18
  19. Emmanuel E. Zervos · 1 shared paper, 2024 · strength 0.18
  20. Ramtin Agah · 1 shared paper, 2024 · strength 0.18
  21. Alexander S. Rosemurgy · 1 shared paper, 2024 · strength 0.18
  22. Nadia Karen Malik · 1 shared paper, 2022 · strength 0.17
  23. Midhun Malla · 1 shared paper, 2022 · strength 0.17
  24. Richard M. Goldberg · 1 shared paper, 2022 · strength 0.17
  25. Sarbajit Mukherjee · 1 shared paper, 2022 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.